表紙:mRNA合成・製造サービス市場:製品タイプ別、応用分野別、治療分野別、主要地域別:業界動向と世界の予測、2022年~2035年
市場調査レポート
商品コード
1172477

mRNA合成・製造サービス市場:製品タイプ別、応用分野別、治療分野別、主要地域別:業界動向と世界の予測、2022年~2035年

mRNA Synthesis and Manufacturing Services Market by Type of Product (Drug Substances and Drug Products ), Application Area, Therapeutic Area and Key Geographical Regions : Industry Trends and Global Forecasts, 2022-2035

出版日: | 発行: Roots Analysis | ページ情報: 英文 165 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.41円
mRNA合成・製造サービス市場:製品タイプ別、応用分野別、治療分野別、主要地域別:業界動向と世界の予測、2022年~2035年
出版日: 2023年09月01日
発行: Roots Analysis
ページ情報: 英文 165 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートでは、世界のmRNA合成・製造サービス市場について調査し、市場の概要とともに、製品タイプ別、応用分野別、治療分野別、地域別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 イントロダクション

  • mRNAの概要
  • mRNAの構造
  • mRNAワクチンの進化
  • mRNAの製造工程
  • 化学合成/in vitro合成mRNAの応用
  • mRNA合成に伴う課題
  • 一般的にアウトソーシングされた製造業務
  • 製造業務をアウトソーシングするメリット

第4章 市場情勢:mRNAカスタム合成サービスプロバイダー

第5章 mRNAカスタム合成サービスプロバイダー:企業の競争力分析

  • 主なパラメータとスコア
  • 調査手法
  • 競争力分析:小企業
  • 競争力分析:中企業
  • 競争力分析:大企業

第6章 市場情勢:mRNA受託製造サービスプロバイダー

第7章 mRNA受託製造サービスプロバイダー:企業の競争力分析

  • 調査手法
  • 企業の競争力分析:北米に拠点を置くmRNA受託製造サービスプロバイダー
  • 企業の競争力分析:欧州に拠点を置くmRNA受託製造サービスプロバイダー
  • 企業の競争力分析:アジア太平洋に拠点を置くmRNA受託製造サービスプロバイダー

第8章 市場情勢:mRNA合成キットのプロバイダー

  • mRNA合成キット:全体的な市場情勢
  • mRNA合成キット:開発者情勢

第9章 mRNA合成キット:製品の競争力分析

  • 調査手法
  • 製品競争力分析:mRNA合成キット

第10章 企業プロファイル:mRNA合成・製造サービスプロバイダー

  • Aldevron
  • Biomay
  • bioSYNTHESIS
  • eTheRNA
  • Eurogentec
  • TriLink BioTechnologies

第11章 企業プロファイル:mRNA合成キットプロバイダー

  • APExBIO
  • CELLSCRIPT
  • Jena Biosciences
  • New England Biolabs
  • Thermo Fisher Scientific

第12章 臨床試験分析

  • 調査手法
  • mRNAベースの治療薬/ワクチン:臨床試験分析

第13章 パートナーシップとコラボレーション

  • パートナーシップモデル
  • mRNAの合成と製造:パートナーシップとコラボレーション

第14章 可能性の高いパートナーの分析

第15章 製薬業界の大きな取り組み

第16章 市場予測

  • 章の概要
  • 主な仮定と予測調査手法
  • 世界のmRNA合成・製造市場、2022年~2035年

第17章 エグゼクティブインサイト

第18章 付録1:表形式のデータ

第19章 付録2:会社および組織のリスト

図表

LIST OF TABLES

  • Table 4.1 List of mRNA Custom Synthesis Service Providers
  • Table 4.2 mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
  • Table 4.3 mRNA Custom Synthesis Service Providers: Information on Synthesis / Manufacturing Capacity
  • Table 6.1 List of mRNA Contract Manufacturing Service Providers
  • Table 8.1 List of mRNA Synthesis Kits
  • Table 8.2 List of mRNA Synthesis Kits Providers
  • Table 10.1 Aldevron: mRNA Synthesis Focused Services Portfolio
  • Table 10.2 Aldevron: Recent Developments and Future Outlook
  • Table 10.3 Biomay: mRNA Synthesis Focused Services Portfolio
  • Table 10.4 Biomay: Recent Developments and Future Outlook
  • Table 10.5 bioSYNTHESIS: mRNA Synthesis Focused Services Portfolio
  • Table 10.6 bioSYNTHESIS: Recent Developments and Future Outlook
  • Table 10.7 eTheRNA: mRNA Synthesis Focused Services Portfolio
  • Table 10.8 eTheRNA: Recent Developments and Future Outlook
  • Table 10.9 Eurogentec: mRNA Synthesis Focused Services Portfolio
  • Table 10.10 Eurogentec: Recent Developments and Future Outlook
  • Table 10.11 TriLink BioTechnologies: mRNA Synthesis Focused Services Portfolio
  • Table 10.12 TriLink BioTechnologies: Recent Developments and Future Outlook
  • Table 11.1 APExBIO: mRNA Synthesis Kits Portfolio
  • Table 11.2 CELLSCRIPT: mRNA Synthesis Kits Portfolio
  • Table 11.3 Jena Biosciences: mRNA Synthesis Kits Portfolio
  • Table 11.4 New England Biolabs: mRNA Synthesis Kits Portfolio
  • Table 11.5 Thermo Fisher Scientific: mRNA Synthesis Kits Portfolio
  • Table 12.1 mRNA-based Therapeutics / Vaccines: List of Clinical Trials
  • Table 13.1 mRNA Synthesis and Manufacturing: List of Partnerships and Collaborations
  • Table 15.1 Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
  • Table 16.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
  • Table 16.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
  • Table 16.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
  • Table 16.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
  • Table 16.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service(s) Offered
  • Table 16.6 mRNA Custom Synthesis Service Providers: Distribution by Input for Synthesis
  • Table 16.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
  • Table 16.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method(s)
  • Table 16.9 mRNA Custom Synthesis Service Providers: Distribution by Application Area(s)
  • Table 16.10 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation(s)
  • Table 16.11 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
  • Table 16.12 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
  • Table 16.13 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
  • Table 16.14 mRNA Contract Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
  • Table 16.15 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facility
  • Table 16.16 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product(s) Manufactured
  • Table 16.17 mRNA Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
  • Table 16.18 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation(s)
  • Table 16.19 mRNA Synthesis Kits: Distribution by Kit Components
  • Table 16.20 mRNA Synthesis Kits: Distribution by Type of Enzyme(s)
  • Table 16.21 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
  • Table 16.22 mRNA Synthesis Kits: Distribution by mRNA Component Modified
  • Table 16.23 mRNA Synthesis Kits: Distribution by Yield per Reaction
  • Table 16.24 mRNA Synthesis Kits: Distribution by Number of Reactions
  • Table 16.25 mRNA Synthesis Kits: Distribution by Reaction Run-Time
  • Table 16.26 mRNA Synthesis Kits: Distribution by Price of Kits
  • Table 16.27 Most Active Players: Distribution by Number of mRNA Synthesis Kits Offered
  • Table 16.28 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
  • Table 16.29 mRNA Synthesis Kit Providers: Distribution by Company Size
  • Table 16.30 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
  • Table 16.32 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Table 16.33 Clinical Trial Analysis: Distribution by Trial Status
  • Table 16.34 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Table 16.35 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Table 16.36 Clinical Trial Analysis: Distribution by Trial Phase
  • Table 16.37 Clinical Trial Analysis: Distribution by Target Patient Population
  • Table 16.38 Clinical Trial Analysis: Distribution by Therapeutic Area(s)
  • Table 16.39 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Table 16.40 Most Active Players: Distribution by Number of Trials
  • Table 16.41 Clinical Trial Analysis: Distribution by Region
  • Table 16.42 Partnership and Collaborations: Distribution by Year of Partnership
  • Table 16.43 Partnership and Collaborations: Distribution by Type of Partnership
  • Table 16.44 Partnership and Collaborations: Distribution by Year and Type of Partnership
  • Table 16.45 Partnership and Collaborations: Distribution by Type of Product(s)
  • Table 16.46 Partnership and Collaborations: Distribution by Type of Partner
  • Table 16.47 Most Active Players: Distribution by Number of Partnerships
  • Table 16.48 Partnership and Collaborations: Distribution by Local and International Agreements
  • Table 16.49 Partnership and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Table 16.50 Partnership and Collaborations: Distribution by Region
  • Table 16.51 Global mRNA Synthesis and Manufacturing Market, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.52 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2022- 2035 (USD Billion)
  • Table 16.53 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs) Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.54 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs) Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.55 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Billion)
  • Table 16.56 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.57 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.58 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
  • Table 16.59 mRNA Synthesis and Manufacturing Market for Infectious Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.60 mRNA Synthesis and Manufacturing Market for Oncological Disorders, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.61 mRNA Synthesis and Manufacturing Market for Other Diseases, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.62 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2022 and 2035 (USD Billion)
  • Table 16.63 mRNA Synthesis and Manufacturing Market in North America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.64 mRNA Synthesis and Manufacturing Market in Europe, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.65 mRNA Synthesis and Manufacturing Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.66 mRNA Synthesis and Manufacturing Market in Latin America, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.67 mRNA Synthesis and Manufacturing Market in MENA, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)
  • Table 16.68 mRNA Synthesis and Manufacturing Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2022-2035 (USD Billion)

LIST OF FIGURES

  • Figure 2.1 Executive Summary: Overall Market Landscape of mRNA Custom Synthesis Service Providers
  • Figure 2.2 Executive Summary: Overall Market Landscape of mRNA Contract Manufacturing Service Providers
  • Figure 2.3 Executive Summary: Overall Market Landscape of mRNA Synthesis Kits
  • Figure 2.4 Executive Summary: Clinical Trial Analysis
  • Figure 2.5 Executive Summary: Partnership and Collaborations
  • Figure 2.6 Executive Summary: Likely Partners Analysis
  • Figure 2.7 Executive Summary: Big Pharma Initiatives
  • Figure 2.8 Executive Summary: Market Forecast and Opportunity Analysis
  • Figure 3.1 Structure of mRNA
  • Figure 3.2 Evolution of mRNA Vaccines
  • Figure 3.3 Chemical Synthesis of mRNA
  • Figure 3.4 In vitro Synthesis of mRNA
  • Figure 4.1 mRNA Custom Synthesis Service Providers: Distribution by Year of Establishment
  • Figure 4.2 mRNA Custom Synthesis Service Providers: Distribution by Company Size
  • Figure 4.3 mRNA Custom Synthesis Service Providers: Distribution by Location of Headquarters
  • Figure 4.4 mRNA Custom Synthesis Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 4.5 mRNA Custom Synthesis Service Providers: Distribution by Type of Service(s) Offered
  • Figure 4.6 mRNA Custom Synthesis Service Providers: Distribution by Input for Synthesis
  • Figure 4.7 mRNA Custom Synthesis Service Providers: Distribution by Structural Modification
  • Figure 4.8 mRNA Custom Synthesis Service Providers: Distribution by Type of Purification Method(s)
  • Figure 4.9 mRNA Custom Synthesis Service Providers: Distribution by Application Area(s)
  • Figure 4.10 mRNA Custom Synthesis Service Providers: Distribution by Scale of Operation(s)
  • Figure 5.1 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Small Companies)
  • Figure 5.2 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Small Companies)
  • Figure 5.3 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Mid-Sized Companies)
  • Figure 5.4 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Mid-Sized Companies)
  • Figure 5.5 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Custom Synthesis Service Providers (Large Companies)
  • Figure 5.6 Company Competitiveness Analysis: Spider Web Analysis of mRNA Custom Synthesis Service Providers (Large Companies)
  • Figure 6.1 mRNA Contract Manufacturing Service Providers: Distribution by Year of Establishment
  • Figure 6.2 mRNA Contract Manufacturing Service Providers: Distribution by Company Size
  • Figure 6.3 mRNA Contract Manufacturing Service Providers: Distribution by Location of Headquarters
  • Figure 6.4 mRNA Contract Manufacturing Service Providers: Distribution by Company Size and Location of Headquarters
  • Figure 6.5 mRNA Contract Manufacturing Service Providers: Distribution by Location of Manufacturing Facility
  • Figure 6.6 mRNA Contract Manufacturing Service Providers: Distribution by Type of Product(s) Manufactured
  • Figure 6.7 mRNA Contract Manufacturing Service Providers: Distribution by Type of Service(s) Offered
  • Figure 6.8 mRNA Contract Manufacturing Service Providers: Distribution by Scale of Operation(s)
  • Figure 7.1 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in North America
  • Figure 7.2 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in North America
  • Figure 7.3 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in Europe
  • Figure 7.4 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in Europe
  • Figure 7.5 Company Competitiveness Analysis: Dot-Plot Representation of mRNA Contract Manufacturing Service Providers based in Asia-Pacific
  • Figure 7.6 Company Competitiveness Analysis: Spider Web Analysis of mRNA Contract Manufacturing Service Providers based in Asia-Pacific
  • Figure 8.1 mRNA Synthesis Kits: Distribution by Kit Components
  • Figure 8.2 mRNA Synthesis Kits: Distribution by Type of Enzyme(s)
  • Figure 8.3 mRNA Synthesis Kits: Distribution by Type of Enzyme Mix Used
  • Figure 8.4 mRNA Synthesis Kits: Distribution by mRNA Component Modified
  • Figure 8.5 mRNA Synthesis Kits: Distribution by Yield per Reaction
  • Figure 8.6 mRNA Synthesis Kits: Distribution by Number of Reactions
  • Figure 8.7 mRNA Synthesis Kits: Distribution by Reaction Run-Time
  • Figure 8.8 mRNA Synthesis Kits: Distribution by Price of Kits
  • Figure 8.9 Most Active Players: Distribution by Number of mRNA Synthesis Kits Offered
  • Figure 8.10 mRNA Synthesis Kit Providers: Distribution by Year of Establishment
  • Figure 8.11 mRNA Synthesis Kit Providers: Distribution by Company Size
  • Figure 8.12 mRNA Synthesis Kit Providers: Distribution by Location of Headquarters
  • Figure 9.1 Product Competitiveness Analysis: Dot-Plot Representation of mRNA Synthesis Kits
  • Figure 9.2 Product Competitiveness Analysis: Dot-Plot Representation of Top mRNA Synthesis Kits
  • Figure 12.1 Clinical Trial Analysis: Distribution by Trial Registration Year
  • Figure 12.2 Clinical Trial Analysis: Distribution by Trial Status
  • Figure 12.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Patients Enrolled
  • Figure 12.4 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
  • Figure 12.5 Clinical Trial Analysis: Distribution by Trial Phase
  • Figure 12.6 Clinical Trial Analysis: Distribution by Target Patient Population
  • Figure 12.7 Clinical Trial Analysis: Distribution by Therapeutic Area(s)
  • Figure 12.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
  • Figure 12.9 Most Active Players: Analysis by Number of Trials
  • Figure 12.10 Clinical Trial Analysis: Distribution by Region
  • Figure 13.1 Partnership and Collaborations: Distribution by Year of Partnership
  • Figure 13.2 Partnership and Collaborations: Distribution by Type of Partnership
  • Figure 13.3 Partnership and Collaborations: Distribution by Year and Type of Partnership
  • Figure 13.4 Partnership and Collaborations: Distribution by Type of Product(s)
  • Figure 13.5 Partnership and Collaborations: Distribution by Type of Partner
  • Figure 13.6 Most Active Players: Analysis by Number of Partnerships
  • Figure 13.7 Partnership and Collaborations: Distribution by Local and International Agreements
  • Figure 13.8 Partnership and Collaborations: Distribution by Intercontinental and Intracontinental Agreements
  • Figure 13.9 Partnership and Collaborations: Distribution by Region
  • Figure 14.1 Likely Partners Analysis: Likely Partners based in North America
  • Figure 14.2 Likely Partners Analysis: Most Likely Partners based in North America
  • Figure 14.3 Likely Partners Analysis: Likely Partners based in Europe
  • Figure 14.4 Likely Partners Analysis: Most Likely Partners based in Europe
  • Figure 14.5 Likely Partners Analysis: Likely Partners based in Asia-Pacific and Rest of the World
  • Figure 14.6 Likely Partners Analysis: Most Likely Partners based in Asia-Pacific and Rest of the World
  • Figure 15.1 Competitive Benchmarking of Big Pharma Players: Harvey Ball Analysis
  • Figure 15.2 Competitive Benchmarking of Big Pharma Players: Spider Web Analysis
  • Figure 16.1 Global mRNA Synthesis and Manufacturing Market, 2022-2035
  • Figure 16.1 mRNA Synthesis and Manufacturing Market: Distribution by Type of Product, 2022-2035 (USD Billion)
  • Figure 16.2 mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), 2022-2035 (USD Billion)
  • Figure 16.3 mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), 2022-2035 (USD Billion)
  • Figure 16.4 mRNA Synthesis and Manufacturing Market: Distribution by Application Area, 2022-2035 (USD Billion)
  • Figure 16.5 mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035 (USD Billion)
  • Figure 16.6 mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035 (USD Billion)
  • Figure 16.7 mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
  • Figure 16.8 mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035 (USD Billion)
  • Figure 16.9 mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035 (USD Billion)
  • Figure 16.10 mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035 (USD Billion)
  • Figure 16.11 mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2022 and 2035 (USD Billion)
  • Figure 16.12 mRNA Synthesis and Manufacturing Market in North America, 2022-2035 (USD Billion)
  • Figure 16.13 mRNA Synthesis and Manufacturing Market in Europe, 2022-2035 (USD Billion)
  • Figure 16.14 mRNA Synthesis and Manufacturing Market in Asia-Pacific, 2022-2035 (USD Billion)
  • Figure 16.15 mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035 (USD Billion)
  • Figure 16.16 mRNA Synthesis and Manufacturing Market in MENA, 2022-2035 (USD Billion)
  • Figure 16.17 mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035, USD Billion
目次
Product Code: RA100401

INTRODUCTION

In the past few years, messenger ribonucleic acid (mRNA) has emerged as one of the key therapeutic modalities in the modern healthcare industry. Post the onset of the COVID-19 pandemic, mRNA therapeutics and mRNA vaccines have garnered significant attention as they have evolved as a revolutionary novel drug class for the treatment of COVID-19, as well as several other diseases, such as oncological disorders, infectious diseases and genetic disorders. Presently, more than 195 mRNA therapeutics / mRNA vaccines are under development or commercialized for the treatment of a variety of indications. As a result, there is an evident increase in the demand for mRNA manufacturing capacity. Fundamentally, the production of mRNA therapeutics / mRNA vaccines is complex, cost intensive and requires specialized expertise. Therefore, mRNA therapeutic / vaccine developers are actively exploring avenues that enable them to overcome the existing challenges. Amongst other alternatives, outsourcing has emerged as a lucrative option for mRNA therapeutic / vaccine developers. In the foreseen future, as more of such RNA-based leads mature and move into the clinic and / or get commercialized, we anticipate the mRNA synthesis and manufacturing services market to witness healthy growth.

SCOPE OF THE REPORT

The "mRNA Synthesis and Manufacturing Services Market (2nd Edition), 2022-2035: Distribution by Type of Product (Drug Substances (APIs) and Drug Products (FDFs)), Application Area(s) (mRNA-based Vaccines and mRNA-based Therapeutics), Therapeutic Area(s) (Infectious Diseases, Oncological Disorders and Other Diseases) and Key Geographical Regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World): Industry Trends and Global Forecasts" report features an extensive study of the current market landscape and future opportunity for the players involved in the synthesis and manufacturing of research- and GMP-grade mRNA for use in the development of therapeutics and vaccines. The report answers many key questions related to this domain.

Benefits and Growing Demand for mRNA Therapeutics / mRNA Vaccines

mRNA therapeutics and mRNA vaccines have emerged as a promising alternative over conventional treatment approaches owing to their multiple benefits, including shorter development timelines, higher biological efficiency, and versatile delivery platforms at reduced toxicity levels. It is worth highlighting that mRNA therapeutics / mRNA vaccines are anticipated to become a powerful therapeutic modality for the treatment of a variety of refractory diseases, including oncological disorders, metabolic disorders, infectious diseases, cardiovascular disorders, cerebrovascular diseases and other diseases.

Need for Outsourcing mRNA Synthesis and Manufacturing Services to Contract Manufacturers

The synthesis and manufacturing of mRNA therapeutics and mRNA vaccines is fraught with several challenges as the production of such biomolecules is complex, cost intensive and requires specialized expertise. Scaling up the manufacturing of mRNA is associated with a number of challenges, mostly related to process development, and maintaining purity and stability. Moreover, some of the processes associated with mRNA production, such as purification, involve the use of hazardous solvents / materials. Once manufactured, mRNA therapeutics / mRNA vaccines need to be stored in conditions that do not compromise their stability (thereby, requiring specialized facilities and cold chain transportation). Further, they also require appropriate drug delivery systems to efficiently administer the intervention (in a manner that they can avoid degradation by cellular endonucleases). Given such technical and operational challenges associated with the production of RNA-based products, innovators in the biopharmaceutical industry are increasingly relying on the contract service providers. The COVID-19 pandemic caused a notable surge in the outsourcing activity, with vaccine developers entering into strategic deals with contract service providers to cater to the urgent global demand.

Current Market Landscape of mRNA Synthesis and Manufacturing Service Providers

The mRNA synthesis and manufacturing service providers landscape features a mix of over 70 large, mid-sized and small companies, which claim to have the required expertise to offer various services for the synthesis and manufacturing of mRNAs across different scales of operations, worldwide. In addition to this, more than 95 mRNA synthesis kits, that contain reagents for the synthesis of research grade mRNAs, are currently available in the market. Recent developments in this segment of the biopharmaceutical industry indicate that the service providers are upgrading their capabilities and infrastructure to accommodate the current and anticipated demand for this novel class of biologics.

Key Drivers in the mRNA Synthesis and Manufacturing Services Market

The success of anti-COVID-19 vaccines has created an enormous need for the consistent supply of these novel vaccines. In the coming decade, several promising leads, specifically those exhibiting enhanced efficacy, are anticipated to be commercially launched. Moreover, considering the active involvement of big pharma players, as well as new entrants, the development pipeline of mRNA drugs is likely to grow further. The big pharma players have undertaken several initiatives, including strengthening mRNA-based product portfolio, entering into strategic deals and making significant financial investments. Therefore, the growing demand for mRNA as a drug agent, lack of manufacturing capabilities and the need for independent geographical supply chains has prompted the mRNA drug developers to outsource various operations involved in mRNA synthesis to the service providers.

Market Size of the mRNA Synthesis and Manufacturing Services Market

Driven by the rising interest in R&D activities and the demand for mRNA-based products, the future opportunities and growth associated with the mRNA synthesis and manufacturing market is anticipated to witness a noteworthy growth in the foreseen future. Specifically, in terms of type of product, the market is anticipated to be driven by contract manufacturing of mRNA vaccines. In addition to this, presently, close to 70% of the market is captured by players based in North America and Europe.

Who are the Key Players in the mRNA Synthesis and Manufacturing Services Market

Examples of key players engaged in this domain (which have also been captured in this report) include Aldevron, APExBIO, Biomay, BioNTech, CELLSCRIPT, CureVac, bioSYNTHESIS, eTheRNA, Eurogentec, Jena Biosciences, Moderna, New England Biolabs, Thermo Fisher Scientific and TriLink BioTechnologies.

The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies. Amongst other elements, the report includes:

  • A general overview of mRNA, highlighting details on its structure and the historical evolution of mRNA vaccines. It also presents information on the in-vitro synthesis of mRNA, its applications in various therapeutic modalities and the challenges associated with the process. Additionally, it features a discussion on the commonly outsourced manufacturing operations and their advantages.
  • A detailed assessment of the overall market landscape of the companies offering mRNA custom synthesis services, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of service(s) offered (custom synthesis, modification, purification, process development, scale-up / manufacturing and fill / finish), input for synthesis (plasmid DNA, mRNA sequence, PCR fragments and other(s)), structural modification (3' modification, 5' modification and base modification), type of purification method(s) (precipitation, chromatography, electrophoresis and other(s)), application area(s) (research and therapeutics / vaccines), scale of operation (research / preclinical, clinical, and commercial) and GMP compliance. It also features information on the mRNA synthesis / manufacturing capacity of the mRNA custom synthesis service providers, highlighting the length of the mRNA manufactured.
  • A detailed competitiveness analysis of mRNA custom synthesis service providers based on supplier strength (in terms of years of experience) and service strength (considering type of service(s) offered, type of modification, scale of operation, GMP compliance and application areas).
  • A comprehensive assessment of the overall market landscape of mRNA contract manufacturing service providers, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, location of manufacturing facilities, type of product(s) manufactured (drug products (FDFs) and drug substances (APIs)), type of service(s) offered (fill / finish, formulation development, purification, process development, analytical testing, and regulatory support) and scale of operation (research / preclinical, clinical and commercial).
  • An in-depth company competitiveness analysis of mRNA contract manufacturing service providers based in North America, Europe and Asia-Pacific. The analysis compares the contract service providers based on supply strength (in terms of years of experience) and service portfolio strength (considering type of service(s) offered, scale of operation, type of product manufactured and number of facilities).
  • A detailed overview of the current market landscape of kits available for mRNA synthesis, based on several relevant parameters, such as type of enzyme, kit components, type of enzyme mix used, mRNA component modified, yield per reaction, number of reactions, reaction run time and kit price. It also features a list of players engaged in the development of mRNA kits, along with analysis based on year of establishment, company size (in terms of number of employees) and location of headquarters. Additionally, it highlights the leading players (in terms of number of mRNA synthesis kits offered) in this domain.
  • A product competitiveness analysis of the mRNA synthesis kits, based on supplier power (in terms of the experience of the developer) and product competitiveness (in terms of type of enzyme, number of kit component(s), type of mRNA component modified, yield, number of reaction(s) and price).
  • Elaborate profiles of key players engaged in the synthesis and manufacturing of mRNA (shortlisted based on strength of service portfolio). Each profile includes a brief overview of the company, along with information on mRNA synthesis service portfolio, additional services offered, recent developments and an informed future outlook.
  • Detailed profiles of the key mRNA synthesis kit providers (shortlisted based on strength of product portfolio). Each profile includes a brief overview of the company, along with information on the mRNA synthesis kits portfolio.
  • An analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target patient population, therapeutic area, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), and regional distribution of trials.
  • A detailed analysis of the recent partnerships inked between stakeholders engaged in this domain, since 2014, covering acquisitions, manufacturing agreements, fill / finish service agreements, supply agreements, service alliance, and other relevant deals.
  • An in-depth analysis of over 35 mRNA-based therapeutics / vaccines developers that are likely to partner with mRNA contract manufacturing service providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company's experience), company size, (in terms of number of employees), pipeline strength (based on the number of mRNA-based drugs in pipeline), highest phase of development, therapeutic area, route of administration and type of candidate being developed.
  • A review of the various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring various insightful representations, such as Harvey ball analysis, spider web analysis, based on several relevant parameters such as funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)).

One of the key objectives of the report was to estimate the current opportunity and the future growth potential of the mRNA synthesis and contract manufacturing services market over the coming years. We have provided an informed estimates on the likely evolution of the market for the period, 2022-2035. Our year-wise projections of the current and forecasted opportunity have been further segmented based on relevant parameters, such as type of product (drug substances (APIs) and drug products (FDFs)), application areas (mRNA-based vaccines and mRNA-based therapeutics), target indications (infectious diseases, oncological disorders and other diseases), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and Rest of the World). In order to account for future uncertainties associated with some of the key parameters and to add robustness to our model, we have provided three market forecast scenarios, portraying the conservative, base and optimistic scenarios of the industry's evolution.

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGY

The data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews / surveys with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Wherever possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts' views

While the focus has been on forecasting the market till 2035, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

KEY QUESTIONS ANSWERED:

Question 1: What are the factors driving mRNA synthesis and manufacturing market?

Answer: The growing demand for mRNA as a drug agent, lack of manufacturing capabilities and the need for independent geographical supply chains has prompted the mRNA drug developers to outsource various operations involved in mRNA synthesis to the service providers.

Question 2: How many players are providing services for custom synthesis of mRNAs?

Answer: Presently, more than 30 companies claim to offer various custom mRNA synthesis services which include mRNA modification, mRNA purification, manufacturing / scale-up, fill / finish and process development related services.

Question 3: How many players are offering mRNA contract manufacturing services for commercial purposes?

Answer: Close to 70% of the players involved in this domain claim to offer mRNA contract manufacturing services at commercial scale; notable examples include Catalent, Curia, Baxter BioPharma Solutions.

Question 4: How many kits are available in the market for the synthesis of mRNA?

Answer: Currently, more than 95 kits available in the market contain the required components for the synthesis of research grade mRNAs used for various applications.

Question 5: Which geographical segment has the highest growth rate in mRNA synthesis and manufacturing market?

Answer: Asia Pacific is likely to grow at the highest CAGR during the period 2022- 2035.

Question 6: Which segment, in terms of type of product, accounts for the largest mRNA synthesis and manufacturing market share?

Answer: Drug substance (APIs), presently, dominates the mRNA synthesis and manufacturing market with a share of close to 70% in 2022. This is attributable to the rising interest in R&D activities and growing demand for the consistent supply of these novel therapeutic / prophylactic interventions for various disease indications.

Question 7: What is the partnership and collaboration trends in mRNA synthesis and manufacturing domain?

Answer: Currently, manufacturing agreements, fill / finish service agreements and supply agreements are common types of partnerships inked by stakeholders in the mRNA synthesis and manufacturing domain.

CHAPTER OUTLINES

  • Chapter 2: Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of the mRNA synthesis and contract manufacturing services market and its likely evolution in the short to mid-term and long term.
  • Chapter 3: provides a general overview of mRNA, highlighting details on its structure and the historical evolution of mRNA vaccines. It also presents information on the in-vitro synthesis of mRNA, its applications in various therapeutic modalities and the challenges associated with the process. Additionally, it features a discussion on the commonly outsourced manufacturing operations and their advantages.
  • Chapter 4: includes detailed assessment of the overall market landscape of the companies offering mRNA custom synthesis services, based on several relevant parameters, such as year of establishment, company size (in terms of number of employees), location of headquarters, type of service(s) offered (custom synthesis, modification, purification, process development, scale-up / manufacturing and fill / finish), input for synthesis (plasmid DNA, mRNA sequence, PCR fragments and other(s)), structural modification (3' modification, 5' modification and base modification), type of purification method(s) (precipitation, chromatography, electrophoresis and other(s)), application area(s) (research and therapeutics / vaccines), scale of operation (research / preclinical, clinical, and commercial) and GMP compliance. It also features information on the mRNA synthesis / manufacturing capacity of the mRNA custom synthesis service providers, highlighting the length of the mRNA manufactured.
  • Chapter 5: presents a detailed competitiveness analysis of mRNA custom synthesis service providers based on supplier strength (in terms of years of experience) and service strength (considering type of service(s) offered, type of modification, scale of operation, GMP compliance and application areas).
  • Chapter 6: includes a comprehensive assessment of the overall market landscape of mRNA contract manufacturing service providers, based on several relevant parameters, including year of establishment, company size (in terms of number of employees), location of headquarters, location of manufacturing facilities, type of product(s) manufactured (drug products (FDFs) and drug substances (APIs)), type of service(s) offered (fill / finish, formulation development, purification, process development, analytical testing, and regulatory support) and scale of operation (research / preclinical, clinical and commercial).
  • Chapter 7: features an in-depth company competitiveness analysis of mRNA contract manufacturing service providers based in North America, Europe and Asia-Pacific. The analysis compares the contract service providers on the basis of various parameters, such as their supply strength (based on their experience in this field) and service portfolio strength (based on type of service(s) offered, scale of operation, type of product manufactured and number of facilities).
  • Chapter 8: provides a detailed overview of the current market landscape of companies engaged in the development of mRNA synthesis kits, based on several relevant parameters, such as type of enzyme, kit components, type of enzyme mix used, mRNA component modified, yield per reaction, number of reactions, reaction run time and kit price. It also features mRNA kit developers landscape based on year of establishment, company size (in terms of number of employees), location of headquarters. Further, it also highlights the leading players (in terms of number of mRNA synthesis kits offered) in this domain.
  • Chapter 9: presents a product competitiveness analysis of the mRNA synthesis kits, based on supplier power (in terms of the experience of the developer) and product competitiveness (in terms of type of enzyme, number of kit component(s), type of mRNA component modified, yield, number of reaction(s) and price).
  • Chapter 10: features profiles of the key players offering services for the synthesis and manufacturing of mRNA (shortlisted based on service portfolio strength). Each profile includes a brief overview of the company, details on mRNA synthesis focused service portfolio, recent developments and an informed future outlook.
  • Chapter 11: includes profiles of the key mRNA synthesis kit providers (shortlisted based on the number of mRNA synthesis kits offered). Each profile includes a brief overview of the company, along with information on the mRNA synthesis kits portfolio.
  • Chapter 12: features a detailed analysis of completed, ongoing and planned clinical studies of mRNA therapeutics and vaccines, based on several relevant parameters, such as trial registration year, trial status, trial phase, target patient population, therapeutic area, type of sponsor / collaborator, leading industry players (in terms of number of trials conducted), and regional distribution of trials.
  • Chapter 13: features an analysis of recent partnerships inked between stakeholders engaged in this domain, since 2014, covering acquisitions, manufacturing agreements, fill / finish service agreements, supply agreements, service alliance, and other relevant deals.
  • Chapter 14: features a comprehensive analysis of over 35 mRNA-based therapeutics / vaccines developers that are likely to partner with mRNA contract manufacturing service providers. These players have been shortlisted based on several relevant parameters, such as developer strength (which takes into account the company's experience), company size, (in terms of number of employees), pipeline strength (based on the number of mRNA-based drugs in pipeline), highest phase of development, therapeutic area, route of administration and type of candidate being developed.
  • Chapter 15: provides the list of various mRNA-focused initiatives undertaken by big pharma players (shortlisted on the basis of the revenues generated in 2021), featuring various insightful representations, such as Harvey ball analysis, spider web analysis, based on several relevant parameters such as funding amount raised, partnership activity, and diversity of product portfolio (in terms of disease indication(s) being treated and focus therapeutic area(s)).
  • Chapter 16: presents a comprehensive market forecast analysis, highlighting the future potential of the market till 2035. We have segregated the current and upcoming opportunity based on type of product (drug substances (APIs) and drug products (FDFs)), application areas (mRNA-based vaccines and mRNA-based therapeutics), target indications (infectious diseases, oncological disorders and other diseases), and key geographical regions (North America, Europe, Asia-Pacific, Latin America, MENA and rest of the world).
  • Chapter 17: provides the transcripts of interviews conducted with key stakeholders in the industry.
  • Chapter 18: is an appendix, which contains tabulated data and numbers for all the figures included in this report.
  • Chapter 19: is an appendix, which contains a list of companies and organizations mentioned in this report.

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Market Segmentations
  • 1.3. Research Methodology
  • 1.4. Key Questions Answered
  • 1.5. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. An Overview of mRNA
  • 3.2. Structure of mRNA
  • 3.3. Evolution of mRNA Vaccines
  • 3.4. mRNA Manufacturing Process
    • 3.4.1. Chemical Synthesis of mRNA
    • 3.4.2. In vitro Synthesis of mRNA
  • 3.5. Applications of Chemically / in vitro Synthesized mRNA
  • 3.6. Challenges Associated with mRNA Synthesis
  • 3.7. Commonly Outsourced Manufacturing Operations
  • 3.8. Advantages of Outsourcing Manufacturing Operations

4. MARKET LANDSCAPE: mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS

  • 4.1. mRNA Custom Synthesis Service Providers: Overall Market Landscape
    • 4.1.1. Analysis by Year of Establishment
    • 4.1.2. Analysis by Company Size
    • 4.1.3. Analysis by Location of Headquarters
    • 4.1.4. Analysis by Company Size and Location of Headquarters
    • 4.1.5. Analysis by Type of Service(s) Offered
    • 4.1.6. Analysis by Input for Synthesis
    • 4.1.7. Analysis by Structural Modification
    • 4.1.8. Analysis by Type of Purification Method(s)
    • 4.1.9. Analysis by Application Area(s)
    • 4.1.10. Analysis by Scale of Operation
    • 4.1.11. mRNA Custom Synthesis Service Providers: Information on Length (Base Pair) of mRNA Manufactured
    • 4.1.12. mRNA Custom Synthesis Service Providers: Information on mRNA Synthesis / Manufacturing Capacity

5. mRNA CUSTOM SYNTHESIS SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Key Parameters and Scores
  • 5.2. Methodology
  • 5.3. Competitiveness Analysis: Small Companies
  • 5.4. Competitiveness Analysis: Mid-Sized Companies
  • 5.5. Competitiveness Analysis: Large Companies

6. MARKET LANDSCAPE: mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS

  • 6.1. mRNA Contract Manufacturing Service Providers: Overall Market Landscape
    • 6.1.1. Analysis by Year of Establishment
    • 6.1.2. Analysis by Company Size
    • 6.1.3. Analysis by Location of Headquarters
    • 6.1.4. Analysis by Company Size and Location of Headquarters
    • 6.1.5. Analysis by Location of Manufacturing Facility
    • 6.1.6. Analysis by Type of Product(s) Manufactured
    • 6.1.7. Analysis by Type of Service(s) Offered
    • 6.1.8. Analysis by Scale of Operation

7. mRNA CONTRACT MANUFACTURING SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

  • 7.1. Methodology
  • 7.2. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in North America
  • 7.3. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Europe
  • 7.4. Company Competitiveness Analysis: mRNA Contract Manufacturing Service Providers based in Asia-Pacific

8. MARKET LANDSCAPE: mRNA SYNTHESIS KIT PROVIDERS

  • 8.1. mRNA Synthesis Kits: Overall Market Landscape
    • 8.1.1. Analysis by Kit Components
    • 8.1.2. Analysis by Type of Enzyme
    • 8.1.3. Analysis by Type of Enzyme Mix Used
    • 8.1.4. Analysis by mRNA Component Modified
    • 8.1.5. Analysis by Yield per Reaction
    • 8.1.6. Analysis by Number of Reactions
    • 8.1.7. Analysis by Reaction Run-Time
    • 8.1.8. Analysis by Price of Kits
    • 8.1.9. Most Active Players: Analysis by Number of mRNA Synthesis Kits Offered
  • 8.2. mRNA Synthesis Kits: Developer Landscape
    • 8.2.1. Analysis by Year of Establishment
    • 8.2.2. Analysis by Company Size
    • 8.2.3. Analysis by Location of Headquarters

9. mRNA SYNTHESIS KITS: PRODUCT COMPETITIVENESS ANALYSIS

  • 9.1. Methodology
  • 9.2. Product Competitiveness Analysis: mRNA Synthesis Kits

10. COMPANY PROFILES: mRNA SYNTHESIS AND MANUFACTURING SERVICE PROVIDERS

  • 10.1. Aldevron
    • 10.1.1. Company Overview
    • 10.1.2. mRNA Synthesis Focused Services Portfolio
    • 10.1.3. Recent Developments and Future Outlook
  • 10.2. Biomay
    • 10.2.1. Company Overview
    • 10.2.2. mRNA Synthesis Focused Services Portfolio
    • 10.2.3. Recent Developments and Future Outlook
  • 10.3. bioSYNTHESIS
    • 10.3.1. Company Overview
    • 10.3.2. mRNA Synthesis Focused Services Portfolio
    • 10.3.3. Future Outlook
  • 10.4. eTheRNA
    • 10.4.1. Company Overview
    • 10.4.2. mRNA Synthesis Focused Services Portfolio
    • 10.4.3. Recent Developments and Future Outlook
  • 10.5. Eurogentec
    • 10.5.1. Company Overview
    • 10.5.2. mRNA Synthesis Focused Services Portfolio
    • 10.5.3. Recent Developments and Future Outlook
  • 10.6. TriLink BioTechnologies
    • 10.6.1. Company Overview
    • 10.6.2. mRNA Synthesis Focused Services Portfolio
    • 10.6.3. Recent Developments and Future Outlook

11. COMPANY PROFILES: mRNA SYNTHESIS KIT PROVIDERS

  • 11.1. APExBIO
    • 11.1.1. Company Overview
    • 11.1.2. mRNA Synthesis Kits Portfolio
  • 11.2. CELLSCRIPT
    • 11.2.1. Company Overview
    • 11.2.2. mRNA Synthesis Kits Portfolio
  • 11.3. Jena Biosciences
    • 11.3.1. Company Overview
    • 11.3.2. mRNA Synthesis Kits Portfolio
  • 11.4. New England Biolabs
    • 11.4.1. Company Overview
    • 11.4.2. mRNA Synthesis Kits Portfolio
  • 11.5. Thermo Fisher Scientific
    • 11.5.1. Company Overview
    • 11.5.2. mRNA Synthesis Kits Portfolio

12. CLINICAL TRIAL ANALYSIS

  • 12.1. Methodology
  • 12.2. mRNA-based Therapeutics / Vaccines: Clinical Trial Analysis
    • 12.2.1. Analysis by Trial Registration Year
    • 12.2.2 Analysis by Trial Status
    • 12.2.3. Analysis by Trial Registration Year and Patients Enrolled
    • 12.2.4. Analysis by Trial Registration Year and Trial Status
    • 12.2.5. Analysis by Trial Phase
    • 12.2.6. Analysis by Target Patient Population
    • 12.2.7. Analysis by Therapeutic Area
    • 12.2.8. Analysis by Type of Sponsor / Collaborator
    • 12.2.9. Most Active Players: Analysis by Number of Trials
    • 12.2.10. Analysis by Region

13. PARTNERSHIP AND COLLABORATIONS

  • 13.1. Partnership Models
  • 13.2. mRNA Synthesis and Manufacturing: Partnerships and Collaborations
    • 13.1.1. Analysis by Year of Partnership
    • 13.1.2. Analysis by Type of Partnership
    • 13.1.3. Analysis by Year and Type of Partnership
    • 13.1.4. Analysis by Type of Product
    • 13.1.5. Analysis by Type of Partner
    • 13.1.6. Most Active Players: Analysis by Number of Partnerships
    • 13.1.7. Analysis by Local and International Agreements
    • 13.1.8. Analysis by Intercontinental and Intracontinental Agreements
    • 13.1.9. Analysis by Region

14. LIKELY PARTNERS ANALYSIS

  • 14.1. Methodology
  • 14.2. Likely Partners based in North America
    • 14.2.1 Most Likely Partners based in North America
  • 14.3. Likely Partners based in Europe
    • 14.3.1 Most Likely Partners based in Europe
  • 14.4. Likely Partners based in Asia Pacific and Rest of the World
    • 14.4.1 Most Likely Partners based in Asia Pacific and Rest of the World

15. BIG PHARMA INITIATIVES

  • 15.1. Methodology
  • 15.2. Big Pharma Players: List of mRNA-based Therapeutics / Vaccines Focused Initiatives
  • 15.3. Competitive Benchmarking of Big Pharma Players
    • 15.3.1. Harvey Ball Analysis
    • 15.3.2. Spider Web Analysis

16. MARKET FORECAST

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Forecast Methodology
  • 16.3. Global mRNA Synthesis and Manufacturing Market, 2022-2035
    • 16.3.1. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Type of Product
      • 16.3.1.1. mRNA Synthesis and Manufacturing Market for Drug Substances (APIs), 2022-2035
      • 16.3.1.2. mRNA Synthesis and Manufacturing Market for Drug Products (FDFs), 2022-2035
    • 16.3.2. mRNA Synthesis and Manufacturing Market, 2022-2035: Distribution by Application Area,
      • 16.3.2.1. mRNA Synthesis and Manufacturing Market for mRNA-based Vaccines, 2022-2035
      • 16.3.2.2. mRNA Synthesis and Manufacturing Market for mRNA-based Therapeutics, 2022-2035
    • 16.3.3. mRNA Synthesis and Manufacturing Market: Distribution by Therapeutic Area, 2022, 2025 and 2035
      • 16.3.3.1. mRNA Synthesis and Manufacturing Market for Infectious Diseases, 2022-2035
      • 16.3.3.1. mRNA Synthesis and Manufacturing Market for Oncological Disorders, 2022-2035
      • 16.3.3.1. mRNA Synthesis and Manufacturing Market for Other Diseases, 2022-2035
    • 16.3.4. mRNA Synthesis and Manufacturing Market: Distribution by Geography, 2025 and 2035 (USD Billion)
      • 16.3.4.1. mRNA Synthesis and Manufacturing Market in North America, 2022-2035
      • 16.3.4.2. mRNA Synthesis and Manufacturing Market in Europe, 2022-2035
      • 16.3.4.3. mRNA Synthesis and Manufacturing Market in Asia Pacific, 2022-2035
      • 16.3.4.4. mRNA Synthesis and Manufacturing Market in Latin America, 2022-2035
      • 16.3.4.5. mRNA Synthesis and Manufacturing Market in MENA, 2022-2035
      • 16.3.4.6. mRNA Synthesis and Manufacturing Market in Rest of the World, 2022-2035

17. EXECUTIVE INSIGHTS

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS